Home 2018-02-13T14:04:26+00:00

Advancing patient care through molecular diagnostic testing

Interpace Diagnostics develops molecular diagnostic tests. You can be assured that all of the molecular tests we offer are driven by rigorous, validated science.

We power the future of molecular diagnostics, delivering cutting-edge and much-needed mutational analysis that helps risk-stratify for thyroid, pancreatic, and other cancers to better inform treatment decisions. The unique molecular diagnostic tests we offer enable healthcare providers to avoid unnecessary surgeries and better assess the risk of cancer progression in their patients.

Our molecular diagnostic tests provide unparalleled accuracy and clarity to improve outcomes in patients facing a cancer diagnosis.

Interpace Diagnostics Molecular Tests


ThyGenX ThyraMIR logos

ThyGenX® Thyroid Oncogene Panel and ThyraMIR™ Thyroid miRNA Classifier molecular testing that aids in the diagnosis of thyroid nodules by identifying genetic alterations associated with thyroid cancer

I am a physician
I am a patient


PancraGen logo

PancraGEN® is a unique, DNA-based, integrated molecular pathology test that assesses the risk of cancer in pancreatic cysts, helping you to optimally manage each individual patient.

I am a physician
I am a patient


RespriDx® can determine whether neoplastic deposits represent metastases or new primary lung cancer.

Learn More

In the Pipeline: Looking Toward the Future of Molecular Diagnostics

We constantly explore areas for the future, invest in research and partnerships, seek opportunities to expand our molecular diagnostics capabilities and serve additional unmet needs in molecular diagnostic testing.

Barrett’s Esophagus

Molecular diagnostic test to determine the risk of progressing to esophageal cancer in patients with Barrett’s Esophagus

BarreGEN Logo

Pancreatobiliary Cancer

Late-stage development of a test to assess pancreatobiliary cancer risk by testing tissue taken from biliary stricture brushings


Interpace Diagnostics’ CEO Interviewed on The RedChip Money Report

PARSIPPANY, N.J., Feb 22, 2018 (GLOBE NEWSWIRE via COMTEX) -- Interpace Diagnostics Group, Inc. IDXG, +11.37% ("Interpace" or "the Company"), a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests and pathology services for [...]

View All